ImmuCell: First Defense With Better Execution
ImmuCell Corp ICCC
$11.21
▲ +1.36%
(+$0.15)
⬆️ Above Yest. High
🎈 Low Float
🗓️ Earnings Next Week
Open
$10.98
Prev Close
$11.06
Day Range
$10.97 – $11.35
52W Range
$4.52 – $12.10
Market Cap
$101.41M
Beta
0.54
EPS (TTM)
$-0.06
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1987-05-01 |
| Shares Out. | 9,050,000 |
| Website | immucell.com/ ↗ |
| Phone | 12078782770 |
| Employees | 73 |
| Revenue | $10.4M |
| Gross Profit | $4.7M |
| Net Income | $1.9M |
| Free Cash Flow | $3.4M |
| Total Assets | $44.1M |
| Total Liabilities | $15.0M |
| Equity | $29.1M |
About ImmuCell Corp
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
ImmuCell Corp is a publicly traded company under the ticker symbol ICCC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2021-12-01)